{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:08:29Z","timestamp":1794582509643,"version":"4.9.1"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,4,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Alzheimer\u2019s Disease (AD), affecting a large population worldwide is characterized by the\nloss of memory and learning ability in the old population. The enzyme Acetylcholinesterase Enzyme\n(AChE) is the key enzyme in the hydrolysis of the neurotransmitter acetylcholine and is also the target\nof most of the clinically used drugs for the treatment of AD but these drugs provide only symptomatic\ntreatment and have the limitation of loss of therapeutic efficacy with time. The development of different\nstrategies targeting the AChE enzyme along with other targets like Butyl Cholinesterase (BChE),\namyloid-\u03b2 (A\u03b2), \u03b2-secretase-1 (BACE), metals antioxidant properties and free radical scavenging capacity\nhas been focused in recent years. Literature search was conducted for the molecules and their\nrational design which have shown inhibition for AChE and the other abovementioned targets. Several\nhybrid molecules incorporating the main sub-structures derived from diverse chemotypes like acridine,\nquinoline, carbamates, and other heterocyclic analogs have shown desired pharmacological activity\nwith a good profile in a single molecule. It is followed by optimization of the activity through structural\nmodifications guided by structure-activity relationship studies. It has led to the discovery of novel\nmolecules 17b, 20, and 23 with desired AChE inhibition along with desirable activity against other\nabovementioned targets for further pre-clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568026619666190128125912","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:06:29Z","timestamp":1549001189000},"page":"264-275","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Target Enzyme in Alzheimer\u2019s Disease: Acetylcholinesterase Inhibitors"],"prefix":"10.2174","volume":"19","author":[{"given":"Mridula","family":"Saxena","sequence":"first","affiliation":[{"name":"Amity School of Applied Sciences, Amity University, Lucknow-226010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Dubey","sequence":"additional","affiliation":[{"name":"Amity School of Applied Sciences, Amity University, Lucknow-226010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nm0706-780","volume":"12","author":"Mount C.","year":"2006","unstructured":"Mount C, Downton C.  Alzheimer disease: progress or profit?","journal-title":"Nat Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","volume":"69","author":"Cummings J.L.","year":"2007","unstructured":"Cummings JL, Doody R, Clark C.  Disease-modifying therapies for Alzheimer disease: challenges to early intervention.","journal-title":"Neurology"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","volume":"129","author":"Klafki H.W.","year":"2006","unstructured":"Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J.  Therapeutic approaches to Alzheimer\u2019s disease.","journal-title":"Brain"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/gps.1077","volume":"19","author":"Prasher V.P.","year":"2004","unstructured":"Prasher VP.  Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer\u2019s disease in adults with Down syndrome: implications for the intellectual disability population.","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"Cummings J.L.","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K.  Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures.","journal-title":"Alzheimers Res Ther"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3922","volume":"12","author":"Gerald Z.","year":"2013","unstructured":"Gerald Z, Ockert W.  Alzheimer\u2019s disease market: hope deferred.","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"Anand R.","year":"2014","unstructured":"Anand R, Gill KD, Mahdi AA.  Therapeutics of Alzheimer\u2019s disease: Past, present and future.","journal-title":"Neuropharmacology"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543776.2012.701620","volume":"22","author":"","year":"2012","unstructured":".  Pohanka, M. Acetylcholinesterase inhibitors: a patent review\n(2008 - present).","journal-title":"Expert Opin Ther Pat"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"Francis P.T.","year":"1999","unstructured":"Francis PT, Palmer AM, Snape M, Wilcock GK.  The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0009-2797(93)90042-W","volume":"87","author":"Sussman J.L.","year":"1993","unstructured":"Sussman JL, Harel M, Silman I.  Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs.","journal-title":"Chem Biol Interact"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20130013","volume":"453","author":"Nachon F.","year":"2013","unstructured":"Nachon F, Carletti E, Ronco C, Trovaslet M, Nicolet Y, Jean L, Renard PY.  Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer\u2019s drugs targeting acetyl- and butyryl-cholinesterase.","journal-title":"Biochem J"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"Inestrosa N.C.","year":"1996","unstructured":"Inestrosa NC, Alvarez A, P\u00e9rez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J.  Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer\u2019s fibrils: possible role of the peripheral site of the enzyme.","journal-title":"Neuron"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/jmbi.1997.1245","volume":"272","author":"Alvarez A.","year":"1997","unstructured":"Alvarez A, Opazo C, Alarc\u00f3n R, Garrido J, Inestrosa NC.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.","journal-title":"J Mol Biol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1021\/bi0101392","volume":"40","author":"De Ferrari G.V.","year":"2001","unstructured":"De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation.","journal-title":"Biochemistry"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.0602922103","volume":"103","author":"Diamant S.","year":"2006","unstructured":"Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H.  Butyrylcholinesterase attenuates amyloid fibril formation","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000113711","volume":"5","author":"Podoly E.","year":"2008","unstructured":"Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, Huang Y, Livnah O, Langermann S, Wilgus H, Soreq H.  Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation","journal-title":"Neurodegener Dis"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","volume":"271","author":"Watkins P.B.","year":"1994","unstructured":"Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW.  Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease.","journal-title":"JAMA"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","volume":"26","author":"Youdim M.B.H.","year":"2005","unstructured":"Youdim MBH, Buccafusco JJ.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.","journal-title":"Trends Pharmacol Sci"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cbpa.2009.04.619","volume":"13","author":"Bolognesi M.L.","year":"2009","unstructured":"Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C.  Alzheimer\u2019s disease: new approaches to drug discovery.","journal-title":"Curr Opin Chem Biol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","volume":"18","author":"Bajda M.","year":"2011","unstructured":"Bajda M, Guzior N, Ignasik M, Malawska B.  Multi-target-directed ligands in Alzheimer\u2019s disease treatment.","journal-title":"Curr Med Chem"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.2174\/156802611798184409","volume":"11","author":"Rampa A.","year":"2011","unstructured":"Rampa A, Belluti F, Gobbi S, Bisi A.  Hybrid-based multi-target ligands for the treatment of Alzheimer\u2019s disease.","journal-title":"Curr Top Med Chem"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1517\/13543776.2012.701619","volume":"22","author":"de los R\u00edos C.","year":"2012","unstructured":"de los R\u00edos C.  Cholinesterase inhibitors: a patent review (2007 - 2011).","journal-title":"Expert Opin Ther Pat"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"Anand P.","year":"2013","unstructured":"Anand P, Singh B.  A review on cholinesterase inhibitors for Alzheimer\u2019s disease.","journal-title":"Arch Pharm Res"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/0929867321666141106122628","volume":"22","author":"Guzior N.","year":"2015","unstructured":"Guzior N, Wieckowska A, Panek D, Malawska B.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer\u2019s disease.","journal-title":"Curr Med Chem"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1582-4934.2008.00595.x","volume":"13","author":"Biran Y.","year":"2009","unstructured":"Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA.  Pharmacotherapeutic targets in Alzheimer\u2019s disease.","journal-title":"J Cell Mol Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"53519","DOI":"10.1039\/C6RA03455A","volume":"6","author":"Hiremathad A.","year":"2016","unstructured":"Hiremathad A, Chand K, Esteves AR, Cardoso SM, Ramsay RR, Chaves S, Keri RS, Santos MA.  Tacrine-allyl\/propargylcysteine\u2013benzothiazole trihybrids as potential anti-Alzheimer\u2019s drug candidates.","journal-title":"RSC Advances"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/1389557517666161111110121","volume":"17","author":"Matias M.","year":"2017","unstructured":"Matias M, Silvestre S, Falcao A, Alves G.  Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders.","journal-title":"Mini Rev Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11030-015-9628-9","volume":"20","author":"Singh M.","year":"2016","unstructured":"Singh M, Kaur M, Chadha N, Silakari O.  Hybrids: a new paradigm to treat Alzheimer\u2019s disease.","journal-title":"Mol Divers"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2174\/15680266113139990136","volume":"13","author":"Minarini A.","year":"2013","unstructured":"Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V.  Multifunctional tacrine derivatives in Alzheimer\u2019s disease.","journal-title":"Curr Top Med Chem"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","volume":"128","author":"Sameem B.","year":"2017","unstructured":"Sameem B, Saeedi M, Mahdavi M, Shafiee A.  A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=31","first-page":"3000","volume":"17","author":"Lin H.","year":"2017","unstructured":"Lin H, Li Q, Gu K, Zhu J, Jiang X, Chen Y, Sun H.  Therapeutic Agents in Alzheimer\u2019s Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core.","journal-title":"Curr Top Med Chem"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","volume":"151","author":"Ismaili L.","year":"2017","unstructured":"Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J.  Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer\u2019s disease.","journal-title":"Prog Neurobiol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3891\/acta.chem.scand.15-1386","volume":"15","author":"Heilbronn E.","year":"1961","unstructured":"Heilbronn E.  Inhibition of cholinesterases by tetrahydroaminacrin.","journal-title":"Acta Chem Scand"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1556\/ABiol.54.2003.2.7","volume":"54","author":"Rakonczay Z.","year":"2003","unstructured":"Rakonczay Z.  Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer\u2019s disease brain.","journal-title":"Acta Biol Hung"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2003.11.080","volume":"486","author":"Liston D.R.","year":"2004","unstructured":"Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF.  Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer\u2019s disease.","journal-title":"Eur J Pharmacol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/106002809402800612","volume":"28","author":"Crismon M.L.","year":"1994","unstructured":"Crismon ML.  Tacrine: first drug approved for Alzheimer\u2019s disease.","journal-title":"Ann Pharmacother"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/(SICI)1097-0282(199601)38:1<109::AID-BIP9>3.0.CO;2-#","volume":"38","author":"Wlodek S.T.","year":"1996","unstructured":"Wlodek ST, Antosiewicz J, McCammon JA, Straatsma TP, Gilson MK, Briggs JM, Humblet C, Sussman JL.  Binding of tacrine and 6-chlorotacrine by acetylcholinesterase.","journal-title":"Biopolymers"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2125.1998.00776.x","volume":"46","author":"Fontana R.J.","year":"1998","unstructured":"Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang BK, Foster NL, Brown RR, Watkins PB.  Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer\u2019s disease.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","volume":"17","author":"Tumiatti V.","year":"2010","unstructured":"Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C.  Tacrine derivatives and Alzheimer\u2019s disease.","journal-title":"Curr Med Chem"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1567205011310080011","volume":"10","author":"Soukup O.","year":"2013","unstructured":"Soukup O, Jun D, Zdarova-Karasova J, Patocka J, Musilek K, Korabecny J, Krusek J, Kaniakova M, Sepsova V, Mandikova J, Trejtnar F, Pohanka M, Drtinova L, Pavlik M, Tobin G, Kuca K.  A resurrection of 7-MEOTA: a comparison with tacrine.","journal-title":"Curr Alzheimer Res"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/ph4020382","volume":"4","author":"Kozurkova M.","year":"2011","unstructured":"Kozurkova M, Hamulakova S, Gazova Z, Paulikova H, Kristian P.  Neuroactive multifunctional tacrine congeners with cholinesterase, anti-amyloid aggregation and neuroprotective properties.","journal-title":"Pharmaceuticals"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.nurt.2008.10.040","volume":"6","author":"Li W.","year":"2009","unstructured":"Li W, Mak M, Jiang H, Wang Q, Pang Y, Chen K, Han Y.  Novel anti-Alzheimer\u2019s dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets.","journal-title":"Neurotherapeutics"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/jm010308g","volume":"45","author":"Hu M-K.","year":"2002","unstructured":"Hu M-K, Wu LJ, Hsiao G, Yen MH.  Homodimeric tacrine congeners as acetylcholinesterase inhibitors.","journal-title":"J Med Chem"},{"key":"ref=44","author":"Pang Y-P.","year":"","unstructured":"Pang Y-P, Brimijoin S.  Tha analogs useful as cholinesterase inhib\u00acitors. 1997. Patent WO1997021681, Mayo Foundation For Medical Edu-cation And Research, USA."},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/00001756-199903170-00023","volume":"10","author":"Wang H.","year":"1999","unstructured":"Wang H, Carlier PR, Ho WL, Wu DC, Lee NT, Li CP, Pang YP, Han YF.  Effects of bis(7)-tacrine, a novel anti-Alzheimer\u2019s agent, on rat brain AChE.","journal-title":"Neuroreport"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0968-0896(98)00213-2","volume":"7","author":"Carlier P.R.","year":"1999","unstructured":"Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, Wong HS, Pang YP.  Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis.","journal-title":"Bioorg Med Chem"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0960-894X(01)00294-3","volume":"11","author":"Savini L.","year":"2001","unstructured":"Savini L, Campiani G, Gaeta A, Pellerano C, Fattorusso C, Chiasserini L, Fedorko JM, Saxena A.  Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejmech.2009.10.039","volume":"45","author":"Pisoni D.S.","year":"2010","unstructured":"Pisoni DS, da Costa JS, Gamba D, Petzhold CL, Borges ACA, Ceschi MA, Lunardi P, Gon\u00e7alves CAS.  Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones.","journal-title":"Eur J Med Chem"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2003.10.003","volume":"39","author":"Frideling A.","year":"2004","unstructured":"Frideling A, Faure R, Galy J-P, Kenz A, Alkorta I, Elguero J.  Tetrahydroacridin-9-ones, 9-chlorotetrahydroacridines, 9-amino-tetrahydroacridines and 9-(pyrazol-1-yl)-tetrahydroacridines derived from chiral cyclanones.","journal-title":"Eur J Med Chem"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1021\/jo400522m","volume":"78","author":"Ba\u00f1\u00f3n-Caballero A.","year":"2013","unstructured":"Ba\u00f1\u00f3n-Caballero A, Guillena G, N\u00e1jera C.  Solvent-free enantioselective Friedl\u00e4nder condensation with wet 1,1\u2032-binaphthalene-2,2\u2032-diamine-derived prolinamides as organocatalysts.","journal-title":"J Org Chem"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0960-894X(00)80267-X","volume":"1","author":"Desai M.C.","year":"1991","unstructured":"Desai MC, Thadeio PF, Lipinski CA, Liston DR, Spencer RW, Williams IH.  Physical parameters for brian uptake: optimizing log P, log D and pKa of THA.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/ja01510a055","volume":"81","author":"Djerassi C.","year":"1959","unstructured":"Djerassi C, Krakower GW.  Optical Rotatory Dispersion Studies. XXI. Effect of Ring Size.","journal-title":"J Am Chem Soc"},{"key":"ref=53","first-page":"2218","volume":"28","author":"Lopes J.P.B.","year":"2017","unstructured":"Lopes JPB.  Costa, S.d. J.; Ceschi, M.A.; Goncalves, C.A.S.; Konrath, E.L.; Karl, A.L.; Guedes, I.A.; Dardenne, L.E.; Chiral Bistacrine Analogues: Synthesis, Cholinesterase Inhibitory Activity and a Molecular Modeling Approach.","journal-title":"J Braz Chem Soc"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejmech.2012.06.051","volume":"55","author":"Hamulakova S.","year":"2012","unstructured":"Hamulakova S, Janovec L, Hrabinova M, Kristian P, Kuca K, Banasova M, Imrich J.  Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.10.058","volume":"477","author":"Qian S.","year":"2014","unstructured":"Qian S, He L, Mak M, Han Y, Ho CY, Zuo Z.  Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors.","journal-title":"Int J Pharm"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1021\/jm060742o","volume":"49","author":"Elsinghorst P.W.","year":"2006","unstructured":"Elsinghorst PW, Tanarro CMG, G\u00fctschow M.  Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bmc.2010.12.022","volume":"19","author":"Luo W.","year":"2011","unstructured":"Luo W, Li YP, He Y, Huang SL, Tan JH, Ou TM, Li D, Gu LQ, Huang ZS.  Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.","journal-title":"Bioorg Med Chem"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.ejmech.2011.03.058","volume":"46","author":"Luo W.","year":"2011","unstructured":"Luo W, Li Y-P, He Y, Huang S-L, Li D, Gu LQ, Huang ZS.  Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.","journal-title":"Eur J Med Chem"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.ejmech.2011.04.038","volume":"46","author":"Szymanski P.","year":"2011","unstructured":"Szymanski P, Karpi\u0144ski A, Mikiciuk-Olasik E.  Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors.","journal-title":"Eur J Med Chem"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bioorg.2011.05.001","volume":"39","author":"Szyma\u0144ski P.","year":"2011","unstructured":"Szyma\u0144ski P, Markowicz M, Mikiciuk-Olasik E.  Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors.","journal-title":"Bioorg Chem"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejmech.2016.03.077","volume":"116","author":"Zhang C.","year":"2016","unstructured":"Zhang C, Du QY, Chen LD, Wu WH, Liao SY, Yu LH, Liang XT.  Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.ejmech.2011.04.038","volume":"46","author":"Szymanski P.","year":"2011","unstructured":"Szymanski P, Karpi\u0144ski A, Mikiciuk-Olasik E.  Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors.","journal-title":"Eur J Med Chem"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.3390\/ijms130810067","volume":"13","author":"Szyma\u0144ski P.","year":"2012","unstructured":"Szyma\u0144ski P, L\u00e1zni\u010dkov\u00e1 A, L\u00e1zni\u010dek M, Bajda M, Malawska B, Markowicz M, Mikiciuk-Olasik E.  2,3-dihydro-1H-cyclopenta[]quinoline derivatives as acetylcholinesterase inhibitors-synthesis, radiolabeling and biodistribution.","journal-title":"Int J Mol Sci"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.bmc.2012.02.059","volume":"20","author":"Huang L.","year":"2012","unstructured":"Huang L, Su T, Shan W, Luo Z, Sun Y, He F, Li X.  Inhibition of cholinesterase activity and amyloid aggregation by berberine- phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids.","journal-title":"Bioorg Med Chem"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1016\/j.bmc.2013.05.028","volume":"21","author":"Keri R.S.","year":"2013","unstructured":"Keri RS, Quintanova C, Marques SM, Esteves AR, Cardoso SM, Santos MA.  Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer\u2019s disease.","journal-title":"Bioorg Med Chem"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/jm300124p","volume":"55","author":"Wang Y.","year":"2012","unstructured":"Wang Y, Guan XL, Wu PF, Wang CM, Cao H, Li L, Guo XJ, Wang F, Xie N, Jiang FC, Chen JG.  Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases.","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.bmc.2011.03.010","volume":"19","author":"Soto-Ortega D.D.","year":"2011","unstructured":"Soto-Ortega DD, Murphy BP, Gonzalez-Velasquez FJ, Wilson KA, Xie F, Wang Q, Moss MA.  Inhibition of amyloid-\u03b2 aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center.","journal-title":"Bioorg Med Chem"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.bmcl.2011.03.052","volume":"21","author":"Alagille D.","year":"2011","unstructured":"Alagille D, DaCosta H, Baldwin RM, Tamagnan GD.  2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer\u2019s brain.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/jm300124p","volume":"55","author":"Wang Y.","year":"2012","unstructured":"Wang Y, Guan XL, Wu PF, Wang CM, Cao H, Li L, Guo XJ, Wang F, Xie N, Jiang FC, Chen JG.  Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases.","journal-title":"J Med Chem"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1021\/jm300106z","volume":"55","author":"Chen Y.","year":"2012","unstructured":"Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, Lehmann J, Zhang Y.  Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/jm201460y","volume":"55","author":"Fern\u00e1ndez-Bachiller M.I.","year":"2012","unstructured":"Fern\u00e1ndez-Bachiller MI, P\u00e9rez C, Monjas L, Rademann J, Rodr\u00edguez-Franco MI.  New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease, with cholinergic, antioxidant, and \u03b2-amyloid-reducing properties.","journal-title":"J Med Chem"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejmech.2013.03.051","volume":"64","author":"Xie S.S.","year":"2013","unstructured":"Xie SS, Wang XB, Li JY, Yang L, Kong LY.  Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2015.03.040","volume":"95","author":"Xie S.S.","year":"2015","unstructured":"Xie SS, Wang X, Jiang N, Yu W, Wang KDG, Lan JS, Li ZR, Kong LY.  Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2011.09.006","volume":"197","author":"Hornick A.","year":"2011","unstructured":"Hornick A, Lieb A, Vo NP, Rollinger JM, Stuppner H, Prast H.  The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory.","journal-title":"Neuroscience"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2016.05.001","volume":"161","author":"Hamulakova S.","year":"2016","unstructured":"Hamulakova S, Poprac P, Jomova K, Brezova V, Lauro P, Drostinova L, Jun D, Sepsova V, Hrabinova M, Soukup O, Kristian P, Gazova Z, Bednarikova Z, Kuca K, Valko M.  Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer\u2019s disease using multifunctional tacrine-coumarin hybrid molecules.","journal-title":"J Inorg Biochem"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/j.bmc.2014.06.057","volume":"22","author":"Sun Q.","year":"2014","unstructured":"Sun Q, Peng DY, Yang SG, Zhu XL, Yang WC, Yang GF.  Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, A aggregation, and -secretase.","journal-title":"Bioorg Med Chem"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/jm050746d","volume":"49","author":"Rodr\u00edguez-Franco M.I.","year":"2006","unstructured":"Rodr\u00edguez-Franco MI, Fern\u00e1ndez-Bachiller MI, P\u00e9rez C, Hern\u00e1ndez-Ledesma B, Bartolom\u00e9 B.  Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.","journal-title":"J Med Chem"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1021\/jm5010804","volume":"57","author":"Nepovimova E.","year":"2014","unstructured":"Nepovimova E, Uliassi E, Korabecny J, Pe\u00f1a-Altamira LE, Samez S, Pesaresi A, Garcia GE, Bartolini M, Andrisano V, Bergamini C, Fato R, Lamba D, Roberti M, Kuca K, Monti B, Bolognesi ML.  Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-\u03b2 aggregation and to exert anticholinesterase and antioxidant effects.","journal-title":"J Med Chem"},{"key":"ref=79","first-page":"S26","volume":"1","author":"Schneider L.S.","year":"1998","unstructured":"Schneider LS, Anand R, Farlow MR.  Systematic review of the efficacy of rivastigmine for patients with Alzheimer\u2019s disease.","journal-title":"Int J GeriatrPsychopharmacol"},{"key":"ref=80","first-page":"55","volume":"1","author":"Corey-Bloom J.","year":"1998","unstructured":"Corey-Bloom J, Anand R, Veach J.  A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease.","journal-title":"Int J GeriatrPsychopharmacol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"R\u00f6sler M.","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, St\u00e4helin HB, Hartman R, Gharabawi M.  Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial.","journal-title":"BMJ"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(04)90172-5","volume":"26","author":"Finkel S.I.","year":"2004","unstructured":"Finkel SI.  Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease.","journal-title":"Clin Ther"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","volume":"2","author":"Onor M.L.","year":"2007","unstructured":"Onor ML, Trevisiol M, Aguglia E.  Rivastigmine in the treatment of Alzheimer\u2019s disease: an update.","journal-title":"Clin Interv Aging"},{"key":"ref=84","author":"Shakya N.","year":"2006","unstructured":"Shakya N, Fatima Z, Nath C, Saxena AK.  Council Of Scientific and Industrial Research India assignee.Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors. 2006. Patent WO2006070394, July 6."},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jmgm.2008.04.006","volume":"27","author":"Roy K.K.","year":"2008","unstructured":"Roy KK, Dixit A, Saxena AK.  An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis.","journal-title":"J Mol Graph Model"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1021\/ci900049e","volume":"49","author":"Chaudhaery S.S.","year":"2009","unstructured":"Chaudhaery SS, Roy KK, Saxena AK.  Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.","journal-title":"J Chem Inf Model"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1021\/jm100573q","volume":"53","author":"Chaudhaery S.S.","year":"2010","unstructured":"Chaudhaery SS, Roy KK, Shakya N, Saxena G, Sammi SR, Nazir A, Nath C, Saxena AK.  Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.bmc.2012.09.005","volume":"20","author":"Roy K.K.","year":"2012","unstructured":"Roy KK, Tota S, Tripathi T, Chander S, Nath C, Saxena AK.  Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer\u2019s disease.","journal-title":"Bioorg Med Chem"},{"key":"ref=89","author":"Shakya N.","year":"","unstructured":"Shakya N, Fatima Z, Nath C, Saxena AK.  Substituted carbamic acid quinolin-6-yl esters as acetylcholinesterase inhibitors. Eur. Patent No. 1831172"},{"key":"ref=90","author":"Roy K.K.","year":"","unstructured":"Roy KK, Tota SK, Shukla R, Nath C, Saxena AK.  Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates their preparation and use there of as Acetylcholinesterase (AChE) inhibitors for the treatment of Alzheimer\u2019s and other neurodegenerative disease. 2015. US8946261"},{"key":"ref=91","author":"Sen Y.","year":"","unstructured":"Sen Y, Lin F, Qingli D, Rong C.  Jiangsu Xianxiong Pharmaceutical Research Co., Ltd., China assignee. Piperazine compound and its application. 2014. CN102603675"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"10142","DOI":"10.3390\/molecules170910142","volume":"17","author":"Imramovsky A.","year":"2012","unstructured":"Imramovsky A, Stepankova S, Vanco J, Pauk K, Monreal-Ferriz J, Vinsova J, Jampilek J.  Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.","journal-title":"Molecules"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/cn5003539","volume":"6","author":"Bohn P.","year":"2015","unstructured":"Bohn P, Gourand F, Papamicael C, Ibazizene M, Dhilly M, Gembus V.  Alix, Florent.; Mihaela-Liliana, \u0162.; Marsais, F.; Barr\u00e9, L.; Levacheet, V.; Dihydroquinoline carbamate derivatives as \u201cbio-oxidizable\u201d prodrugs for brain delivery of acetylcholinesterase inhibitors: [C] radiosynthesis and biological evaluation.","journal-title":"Chem Neurosci"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.ejmech.2011.02.019","volume":"46","author":"Belluti F.","year":"2011","unstructured":"Belluti F, Bartolini M, Bottegoni G, Bisi A, Cavalli A, Andrisano V, Rampa A.  Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced -amyloid aggregation.","journal-title":"Eur J Med Chem"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2013.06.021","volume":"67","author":"Samadi A.","year":"2013","unstructured":"Samadi A, de la Fuente Revenga M, P\u00e9rez C, Iriepa I, Moraleda I, Rodr\u00edguez-Franco MI, Marco-Contelles J.  Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2012.09.030","volume":"57","author":"Samadi A.","year":"2012","unstructured":"Samadi A, Estrada M, P\u00e9rez C, Rodr\u00edguez-Franco MI, Iriepa I, Moraleda I, Chioua M, Marco-Contelles J.  Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease: synthesis, biological assessment, and molecular modeling.","journal-title":"Eur J Med Chem"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"Bolea I.","year":"2011","unstructured":"Bolea I, Ju\u00e1rez-Jim\u00e9nez J, de Los R\u00edos C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A.  Synthesis, biological evaluation, and molecular modeling of donepezil and -[(5-(benzyloxy)-1-methyl-1-indol-2-yl)methyl]--methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer\u2019s disease.","journal-title":"J Med Chem"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","volume":"75","author":"Bautista-Aguilera O.M.","year":"2014","unstructured":"Bautista-Aguilera OM, Esteban G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J.  Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease.","journal-title":"Eur J Med Chem"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1016\/j.bmcl.2012.04.029","volume":"22","author":"Meng F.C.","year":"2012","unstructured":"Meng FC, Mao F, Shan WJ, Qin F, Huang L, Li XS.  Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejmech.2014.05.056","volume":"82","author":"Alipour M.","year":"2014","unstructured":"Alipour M, Khoobi M, Moradi A, Nadri H, Homayouni Moghadam F, Emami S, Hasanpour Z, Foroumadi A, Shafiee A.  Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives.","journal-title":"Eur J Med Chem"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jep.2004.02.012","volume":"92","author":"Heinrich M.","year":"2004","unstructured":"Heinrich M, Lee Teoh H.  Galanthamine from snowdrop--the development of a modern drug against Alzheimer\u2019s disease from local Caucasian knowledge.","journal-title":"J Ethnopharmacol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/cr040415t","volume":"106","author":"Marco-Contelles J.","year":"2006","unstructured":"Marco-Contelles J, do Carmo Carreiras M, Rodr\u00edguez C, Villarroya M, Garc\u00eda AG.  Synthesis and pharmacology of galantamine.","journal-title":"Chem Rev"},{"key":"ref=103","first-page":"728","volume":"277","author":"Bores G.M.","year":"1996","unstructured":"Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW, Davis L, Vargas HM.  Pharmacological evaluation of novel Alzheimer\u2019s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1517\/13543784.9.10.2393","volume":"9","author":"Sramek J.J.","year":"2000","unstructured":"Sramek JJ, Frackiewicz EJ, Cutler NR.  Review of the acetylcholinesterase inhibitor galanthamine.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.bmc.2015.07.058","volume":"23","author":"Atanasova M.","year":"2015","unstructured":"Atanasova M, Stavrakov G, Philipova I, Zheleva D, Yordanov N, Doytchinova I.  Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity.","journal-title":"Bioorg Med Chem"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T06:03:31Z","timestamp":1558764211000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169426\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190128125912","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}